Investors

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient´s dendritic cells to activate an immune response specific to the patient´s disease. Argos´ most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.


Stock Quote

NASDAQ: ARGS
0.17
- 0.00 (-2.53%)

Day High:
0.17

Day Low:
0.16

Volume:
2,767,077

3:59 PM ET on Oct 17, 2017
Delayed at least 20 minutes.